Skip to Main Content

Paper Details

Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Eur J Cancer
18
2016
Author NameAffiliation
Michael SteffensFederal Institute for Drugs and Medical Devices, University Bonn Medical Faculty
Catharina SchollFederal Institute for Drugs and Medical Devices, University Bonn Medical Faculty
  • 1 - 2

Datasets

Release 1.2